0R15 8540.2617 2.2296% 0R1E 8262.0176 -1.9229% 0M69 17217.5293 36.7556% 0R2V 181.94 0.1872% 0QYR 1423.1256 0.3538% 0QYP 402.3999 -0.7645% 0LCV 126.7 -1.0156% 0RUK 2959.3132 1.277% 0RYA 1718.0 -0.0582% 0RIH 142.0 0.3534% 0RIH 140.48 -1.0704% 0R1O 167.0 9767.0606% 0R1O None None% 0QFP 9785.8682 94.1641% 0M2Z 268.7914 -0.0683% 0VSO 22.315 -37.3262% 0R1I None None% 0QZI 477.0 0.5269% 0QZ0 220.0 0.0% 0NZF 818.1412 64.1535%

Sanara Medtech Inc

Healthcare US SMTI


Last update at 2024-02-20T20:51:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -13.93712M -7.99380M -4.44515M -2.83578M -0.60057M
Minority interest -0.15483M 0.07M -0.31039M -0.22169M -0.22169M
Net income -8.09233M -7.30570M -4.38279M -2.93020M -0.60057M
Selling general administrative 45.98M 28.05M 18.68M 13.07M 5.74M
Selling and marketing expenses - - - - -
Gross profit 39.48M 21.83M 13.97M 10.56M 5.33M
Reconciled depreciation 2.37M 0.60M 0.29M 0.12M 0.08M
Ebit -12.23243M -7.37616M -5.00461M -2.63006M -0.50143M
Ebitda -10.24100M -7.39611M -4.69842M -2.49991M -0.41754M
Depreciation and amortization 1.99M -0.01995M 0.31M 0.13M 0.08M
Non operating income net other -1.70469M - 0.59M - -
Operating income -12.23243M -7.37616M -5.00461M -2.63006M -0.50186M
Other operating expenses 58.08M 31.52M 20.59M 14.40M 6.33M
Interest expense 0.28M 0.00071M 0.01M 0.11M 0.09M
Tax provision -5.84480M - - - -
Interest income - - - - -
Net interest income -0.28475M -0.00071M -0.01153M -0.10592M -0.08659M
Extraordinary items - - - - -
Non recurring - - 0.03M - -
Other items - - - - -
Income tax expense -5.84480M -0.68810M -0.06236M 0.09M 0.01M
Total revenue 45.84M 24.14M 15.59M 11.77M 5.84M
Total operating expenses 51.71M 29.21M 18.97M 13.19M 5.82M
Cost of revenue 6.36M 2.31M 1.62M 1.21M 0.51M
Total other income expense net -1.70469M -0.61764M 0.56M -0.20572M -0.02468M
Discontinued operations - - - - -
Net income from continuing ops -8.09233M -7.99380M -4.44515M -2.83578M -0.60057M
Net income applicable to common shares -7.93750M -7.92191M -4.35644M -2.81409M 0.14M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 61.04M 36.40M 9.83M 11.12M 3.04M
Intangible assets 31.51M 4.73M 3.10M 1.47M 0.05M
Earning assets - - - - -
Other current assets 1.10M 0.92M 0.61M 0.16M 0.03M
Total liab 19.32M 6.24M 3.99M 4.72M 1.93M
Total stockholder equity 41.83M 30.64M 6.15M 6.61M 1.11M
Deferred long term liab - - - - -
Other current liab 11.10M 5.38M 3.14M 2.18M 0.35M
Common stock 0.00830M 0.00768M 0.00630M 0.00357M 0.24M
Capital stock 0.00830M 0.00768M 0.00630M 11.37M 0.24M
Retained earnings -23.39476M -15.23504M -7.03224M -2.67580M -47.46902M
Other liab 6.00M - 0.09M 0.10M 0.03M
Good will 3.60M - - - -
Other assets - - - - -
Cash 8.96M 18.65M 0.46M 6.61M 0.73M
Cash and equivalents - - - - -
Total current liabilities 12.81M 6.02M 3.54M 2.64M 0.40M
Current deferred revenue - - - - -
Net debt -8.13977M -18.22740M 0.03M -4.51301M 0.77M
Short term debt 0.31M 0.20M 0.13M 0.12M -
Short long term debt - - - - -
Short long term debt total 0.82M 0.43M 0.48M 2.10M 1.50M
Other stockholder equity 65.21M 45.87M 13.18M -2.08183M 48.41M
Property plant equipment 1.42M 2.04M 1.15M 0.79M 0.02M
Total current assets 20.62M 24.61M 4.48M 8.86M 0.98M
Long term investments 3.08M 5.02M 1.10M - 1.96M
Net tangible assets 6.72M 25.91M 3.05M -6.22525M -10.78135M
Short term investments - - 1.10M - -
Net receivables 7.00M 2.99M 2.27M 1.34M 0.21M
Long term debt - - - 1.50M 1.50M
Inventory 3.55M 2.05M 1.15M 0.75M 0.47M
Accounts payable 1.39M 0.44M 0.27M 0.34M 0.05M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity -0.10755M - -0.31039M - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - -0.06069M -0.07012M
Additional paid in capital - - - - -
Common stock total equity 0.00830M - 0.00630M 0.00357M 0.24M
Preferred stock total equity - - - - -
Retained earnings total equity -23.39476M - -7.03224M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -20.61651M -19.59114M 0.47M 2.26M 0.98M
Deferred long term asset charges - - - - -
Non current assets total 40.42M 11.79M 5.34M 2.26M 2.06M
Capital lease obligations 0.82M 0.43M 0.48M 0.60M -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -0.25000M -5.28473M -2.74437M -1.10000M -1.10000M
Change to liabilities 2.69M 0.10M 0.09M -0.08464M 0.35M
Total cashflows from investing activities -3.51163M -5.28473M -2.74437M -1.19604M -0.02777M
Net borrowings - - 0.58M 0.58M 0.58M
Total cash from financing activities -0.62735M 28.30M 0.62M 9.80M -0.20810M
Change to operating activities 3.73M 0.65M 0.42M 0.95M 0.94M
Net income -8.09233M -7.99380M -4.44515M -2.83578M -0.60057M
Change in cash -9.69385M 18.20M -6.15656M 6.44M 0.27M
Begin period cash flow 18.65M 0.46M 6.61M 0.18M 0.46M
End period cash flow 8.96M 18.65M 0.46M 6.61M 0.73M
Total cash from operating activities -5.55487M -4.81453M -4.03452M -2.16740M 0.28M
Issuance of capital stock 0.00000M 28.94M - - 0.00000M
Depreciation 2.37M 0.60M 0.29M 0.12M 0.08M
Other cashflows from investing activities -3.11462M - -1.10000M - -
Dividends paid 0.22M - - - 0.22M
Change to inventory -0.51727M -1.15176M -0.71981M -0.28120M 0.26M
Change to account receivables -2.26898M -0.77480M -0.96146M -0.32437M 0.61M
Sale purchase of stock - - 0.04M - -
Other cashflows from financing activities -0.62735M 0.16M -10.78515M 12.00M 0.21M
Change to netincome -0.63598M 3.69M 1.30M 0.39M 0.09M
Capital expenditures 0.75M 0.75M 1.64M 1.71M 0.00848M
Change receivables -2.26898M - -0.96146M - -
Cash flows other operating 0.61M - -4.89189M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes -9.69385M - -6.15656M - -
Change in working capital 0.52M -1.18188M -1.17756M 0.36M 0.71M
Stock based compensation 2.70M 2.67M 1.40M - -
Other non cash items 2.79M 0.43M 0.45M 0.19M 0.09M
Free cash flow -6.30189M -5.56498M -5.67889M -3.87271M 0.27M


  • Previous Close 39.01
  • Market Cap326.77M
  • Volume14923
  • P/E Ratio-
  • Dividend Yield0.42%
  • EBITDA-5.10105M
  • Revenue TTM62.62M
  • Revenue Per Share TTM7.62
  • Gross Profit TTM 39.48M
  • Diluted EPS TTM-1.0

Peer Comparison

Sector: Healthcare Industry: Medical Instruments & Supplies

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Sanara Medtech Inc
-1.01 2.59% 38.00 0.0 0.0 5.37 7.55 5.44 -76.0991
Intuitive Surgical Inc
-1.87 0.49% 376.76 76.39 50.76 16.72 9.14 16.12 52.74
Essilor International SA
0.64 0.63% 101.50 35.39 24.81 3.63 2.20 4.00 16.25
EssilorLuxottica Société anonyme
1.93 0.97% 201.25 35.71 25.13 3.62 2.23 4.00 16.25
Becton Dickinson and Company
0.0 0.0% 240.76 47.65 17.51 3.60 2.69 4.33 19.06

Reports Covered

Stock Research & News


Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It also offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Sanara Medtech Inc

1200 Summit Avenue, Fort Worth, TX, United States, 76102

Key Executives

Name Title Year Born
Mr. Ronald T. Nixon Exec. Chairman 1956
Mr. Zachary B. Fleming Chief Exec. Officer 1975
Mr. Michael D. McNeil CFO & Corp. Sec. 1965
Mr. Callon Nichols Director of Investor Relations NA
Mr. Bill Fitzgerald Compliance Officer NA
Dr. Jane A. Fore Chief Medical Officer NA
Ms. Tricia Matteson Sr. Director of Marketing NA
Ms. Carla Day Director of Customer & Sales Services NA
Dr. Christopher A. Morrison FACHM, FAPWCA, FCCWS, M.D. Pres of Telehealth Services 1970
Dr. Rebecca Erin Mcmahon Pres of R&D 1985

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions